What Femelle 20 Treats: Main Uses and Benefits

Femelle 20 is commonly used across specific therapeutic domains to provide supportive symptomatic management. This combination is indicated for pregnancy prevention, symptoms of Premenstrual Dysphoric Disorder (PMDD), and moderate acne.

---

Support for Pregnancy Prevention

This medication is used as a method of systemic contraception in women of reproductive age. This core function of the combined hormonal therapy offers a supportive benefit that may assist with maintaining functional stability for family planning.

Management of Symptoms

Femelle 20 is applied in clinical settings marked by the recurring, heightened emotional and physical distress of PMDD. It provides symptomatic support that contributes to easing the overall symptom load of severe mood swings, irritability, anxiety, and associated physical symptoms like bloating and breast tenderness. Furthermore, it is relevant for managing certain symptom-driven clinical presentations, specifically providing support for moderate acne vulgaris and assisting with pronounced menstrual symptoms such as pain (dysmenorrhea) and heavy bleeding (menorrhagia).

Quick Fact	Relief for Symptom
Mood	Helps ease severe cyclical mood swings and irritability
Physical	Supports the management of cyclical fluid retention and breast tenderness
Dermatological	May assist with managing moderate acne lesions

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Femelle 20? - Official Regulatory Information

The eligibility profile for Femelle 20 is strictly defined by official regulatory labeling, outlining mandatory exclusions and cautions based on specific patient populations and existing health conditions. This information determines who may be prescribed the medicine.

Absolute Contraindications (Must Not Use)

The medicine is absolutely contraindicated and must not be used by individuals who:

• Have a known or suspected pregnancy.
• Have a documented hypersensitivity or allergic reaction to the active substance (Ulipristal acetate) or any other component.
• Have certain rare hereditary problems, such as severe galactose intolerance.

Restricted or Not Recommended Use

Use is not recommended or requires specific caution for the following populations or conditions:

• Severe Hepatic Impairment: Due to the drug's metabolism, it is not recommended for individuals with severe liver problems.
• Breastfeeding/Lactation: Use is restricted, and breastfeeding is not recommended for a specified period (e.g., 36 hours to one week) after taking the medicine.
• Age: While generally established for adult women of reproductive age, safety and efficacy may not be formally established in prepubertal children.

All patients must be assessed against these regulatory criteria before treatment. The use of this medicine is also subject to a strict 120-hour (5-day) timing constraint relative to the event.

Interactions with other medicines and products

The following information summarizes documented interactions for Femelle 20, derived from regulatory labeling and official drug monographs. Users should refer to the full Prescribing Information for comprehensive details.

---

Contraindicated Combinations

Specific combinations of Direct-Acting Antivirals (DAAs) used to treat Hepatitis C (HCV), such as regimens containing Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Glecaprevir/Pibrentasvir, or Sofosbuvir/Velpatasvir/Voxilaprevir, are strictly contraindicated with Femelle 20 due to the risk of liver enzyme elevation (ALT).

---

Pharmacokinetic Interactions (Altered Exposure)

Femelle 20 components are subject to metabolism, primarily via the cytochrome P450 (CYP) system.

• Decreased Exposure: Medicines that are strong CYP enzyme inducers, such as Phenytoin, Carbamazepine, Rifampicin, and St. John's Wort, accelerate the metabolism of Femelle 20, leading to significantly reduced systemic exposure. This can impact therapeutic effect.
• Increased Exposure: Conversely, strong CYP inhibitors have the potential to increase the concentration of Femelle 20 in the bloodstream.

---

Impact on Co-administered Drugs

Femelle 20 can significantly increase the clearance of certain co-administered drugs, such as the anti-epileptic medication Lamotrigine, resulting in a substantial reduction of the Lamotrigine plasma concentration.

---

Timing and Other Interactions

A specific timing separation must be observed when initiating Femelle 20 after using Ulipristal Acetate emergency contraception. Furthermore, drugs that affect serum potassium levels may have specific pharmacodynamic implications, particularly if the progestogen component of Femelle 20 has anti-mineralocorticoid activity.

Femelle 20, a combination of drospirenone (a progestogen) and ethinylestradiol (an estrogen), exerts its systemic physiological modulation through suppression of the hypothalamic-pituitary-ovarian (HPO) axis. Ethinylestradiol, an agonist at the estrogen receptor, and drospirenone, an agonist at the progesterone receptor, provide negative feedback to the hypothalamus and pituitary gland. This feedback mechanism reduces the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), which, in turn, diminishes the secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) from the anterior pituitary.

The resulting systemic suppression of gonadotropins inhibits follicular development and prevents the mid-cycle LH surge. The downstream cascade is the abolishment of ovarian follicular rupture. Additionally, drospirenone alters the endometrium, reducing its thickness and cellular receptivity. Concurrently, the progestogenic component increases the viscosity and cellular density of the cervical mucus, restricting sperm transit across the cervix. Drospirenone also acts as an antagonist at the mineralocorticoid receptor and the androgen receptor.

How to Use Femelle 20

This section outlines the general administration principles for Femelle 20 (Drospirenone 3 mg / Ethinylestradiol 0.02 mg).

---

Administration Scope

Instruction Entity	Statement
Route of administration	The product is administered via the oral route.
Dosing schedule	The standard regimen is one tablet taken daily for 28 consecutive days, completing one cycle. The cycle is structured as 24 active tablets followed by 4 inert (placebo) tablets.
Timing	The tablet must be taken at approximately the same time each day to maintain steady hormone levels. It may be taken with or without food.
Tablet Order	Tablets must be consumed in the specific sequence indicated on the blister pack to ensure the correct progression from active to placebo days.

---

Procedural Structure

The medication is designed for continuous cyclic use where one tablet is taken every 24 hours. The procedural structure is defined by the following sequence: the 24 active tablets are taken first, followed immediately by the 4 placebo tablets. A new 28-day pack is started the day after the last placebo tablet is taken, without a break. Specific instructions are established for handling missed active tablets based on the time and number of doses missed. If use is started later than Day 1 of the menstrual cycle, a non-hormonal back-up method should be used for the initial 7 consecutive days.

Research evidence / Overview of Studies for Femelle 20

This section summarizes the type of research studies that have been conducted on the drospirenone/ethinylestradiol combination, outlining what was measured and where limitations or research gaps exist. This information is based on regulatory documentation and peer-reviewed literature and contains no clinical recommendations or causal claims about its performance.

---

Evidence for use in Preventing Pregnancy (Contraception)

Research examining this combination for contraception was conducted through large-scale clinical trials that included healthy women of reproductive age. The main goal of these studies was to monitor outcomes related to cycle control and to measure the Pearl Index, a scientific way to estimate the number of pregnancies expected to occur per 100 women using the method for a year. Studies reported specific measurements of the Pearl Index, which are findings describing patterns observed in the studies regarding contraception success under the specific trial conditions. A key limitation is that most efficacy research was studied for comparison against other existing hormonal contraceptives, rather than against a placebo. Long-term effects are not fully established beyond one year, and research is ongoing through observational studies to monitor outcomes over several years.

---

Evidence for use in Managing Premenstrual Dysphoric Disorder (PMDD)

Evidence for this use relies mainly on short-term, randomized, double-blind, placebo-controlled trials (RCTs) applied in research contexts involving fluctuating or unstable symptoms. The primary measurements were outcomes describing episodic or acute changes in emotional and physical distress, along with outcomes reflecting daily functioning or activity level. Research highlights changes measured during the study period in patient-reported severity scores when compared to the placebo group. A significant limitation is that core evidence was studied for only three menstrual cycles; therefore, follow-up durations were limited, and the long-term patterns for sustained symptom management are not well characterized. Furthermore, the evidence base does not extend to women with general pre-menstrual syndrome (PMS).

---

Evidence for use in Supporting Moderate Acne Vulgaris

Research was evaluated in short-term, randomized, double-blind, placebo-controlled trials run over six menstrual cycles. These studies explored outcomes linked to inflammatory or irritative states by monitoring the reduction of individual acne lesions and using the Investigator Static Global Assessment (ISGA) rating of skin condition. Findings describe patterns observed in the studies regarding the reduction of specific acne lesion counts when participants were compared against the placebo group. The primary limitation is that results apply only to the populations studied—women simultaneously seeking systemic contraception—and data for certain groups remain insufficient, with limited data on the formula's use in severe acne.

---

What Remains Uncertain in the Research Landscape

Research helps show what has been observed so far, but several areas of uncertainty remain. Long-term effects are not fully established for certain symptomatic uses, as follow-up durations were limited in key studies for PMDD and acne. Additionally, data for certain groups remain insufficient, meaning the evidence does not provide context for individuals outside the trial characteristics. For painful periods (dysmenorrhea), systematic reviews note that evidence quality varies across studies, and comparative evidence is lacking against all active control drugs, indicating that research is still exploring any differences between this and other hormonal options. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Storage and Disposal of Femelle 20

The storage and handling of Femelle 20 tablets must adhere strictly to official regulatory requirements to ensure product quality and safety.

Storage Requirements

The medication must be stored at Controlled Room Temperature, generally not exceeding 25 C. The tablets should be kept in the original container with the lid tightly closed to provide protection from moisture and light.

Storage Constraint	Requirement
Temperature	Store at 25 C (Controlled Room Temp.)
Protection	Keep protected from moisture, light, and excess heat.
Safety	Keep out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Femelle 20 must not be flushed down the toilet or disposed of in household trash. Disposal must occur through a medicine take-back program or in accordance with local regulations for pharmaceutical waste.